Compare AU

Compare DRUG vs. IXI

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Global Healthcare ETF - Currency Hedged

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the iShares Global Consumer Staples ETF (IXI). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

DRUG

IXI

Popularity

Low

Low

Pearlers invested

64

37

Median incremental investment

$943.50

$996.75

Median investment frequency

Monthly

Monthly

Median total investment

$1,969.68

$2,079.22

Average age group

26 - 35

> 35


Key Summary

DRUG

IXI

Strategy

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

IXI.AX was created on 2006-09-12 by iShares. The fund's investment portfolio concentrates primarily on consumer staples equity. The fund aims to provide investors with the performance of the S&P Global 1200 Consumer Staples Sector Index, before fees and expenses. The index is designed to measure the performance of global consumer staples companies and may include large-, mid- or smallcapitalisation stocks.

Top 3 holdings

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

ISHARES GLOBAL CONSUMER STAPLES ET (99.97 %)

USD CASH (0.21 %)

USD/AUD (0.00 %)

Top 3 industries

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Other (99.92 %)

Communication Services (0.08 %)

Top 3 countries

United States (23.96 %)

Ireland (0.52 %)

France (0.00 %)

United States (99.61 %)

Management fee

0.57 %

0.4 %


Key Summary

DRUG

IXI

Issuer

BetaShares

iShares

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

S&P Global 1200 / Consumer Staples -SEC

Asset class

ETF

ETF

Management fee

0.57 %

0.4 %

Price

$8.49

$94.50

Size

$197.947 million

$139.475 million

10Y return

N/A

84.21 %

Annual distribution yield (5Y)

1.90 %

2.18 %

Market

ASX

ASX

First listed date

08/08/2016

11/03/2009

Purchase fee

$6.50

$6.50


Community Stats

DRUG

IXI

Popularity

Low

Low

Pearlers invested

64

37

Median incremental investment

$943.50

$996.75

Median investment frequency

Monthly

Monthly

Median total investment

$1,969.68

$2,079.22

Average age group

26 - 35

> 35


Pros and Cons

DRUG

IXI

Pros

  • Higher price growth

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

  • Lower price growth

DRUG

IXI

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home